CAMBRIDGE, Mass.--(BUSINESS WIRE)--Inspiration Biopharmaceuticals, Inc. (Inspiration) announced interim clinical results for the company’s two lead product candidates, an intravenous recombinant porcine FVIII (OBI-1) in the treatment of serious bleeds in acquired hemophilia A (AHA) and an intravenous recombinant FIX (IB1001) for the treatment and prevention of bleeding in children less than 12 years of age with hemophilia B. The data were presented in posters at the 54th American Society of Hematology Annual Meeting in Atlanta, Georgia. Inspiration’s OBI-1 investigational drug met the primary endpoint of providing effective or partially effective treatment of serious bleeding in 16 subjects with acquired hemophilia A based on the investigator’s assessment of response to treatment.
